In his first installment in 2025 of the veterinary scene down under, Phil Tucak, BSc, BVMS, shares updates on the organization working on the advancement of the statutory regulation across Australia, ...

GEN uncovers seven biopharma-related trends based on interviews with experts and other industry stakeholders, as well as ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...

But there’s no reason to think 2025 will be any calmer. That’s not just because Trump is likely to preside over a volatile ...

In the realm of male enhancement, Vivalis has emerged as a noteworthy contender, promising to elevate sexual performance and ...